中文摘要：

目的探讨蛋白激酶Bd（PKBα）基因第1，2，4内含子区4个单核甘酸多态性与西酞普兰抗抑郁疗效及副反应之间的关联。方法收集符合美国精神障碍诊断与统计手册第4版（DSM—IV）重性抑郁障碍诊断标准的患者，共104例。使用西酞普兰抗抑郁治疗，在治疗后1周、2周、4周时评定相关量表，应用聚合酶联反应（PCR）和DNA直接测序技术，检测PKB多态性位点基因型；使用SPSS13．0统计软件进行分析。结果①PKBα rs2494738与西酞普兰抗抑郁疗效之间相关联（等位基因：OR=0．139，P=0．011）；携带G等位基因抑郁症患者西酞普兰治疗抗抑郁疗效优于携带A等位基因者。②rs2494738基因型可能与口干副反应弱关联（Х^2=6．730，P=0．035）。结论PKBα rs2494738位点可能与西酞普兰治疗抗抑郁疗效及某些副反应之间有关联。

英文摘要：

Objective To examine the association between protein kinase Bα gene first,second and forth intron polymorphism and citalopram antidepressant clinical efficacy and side effects. Methods The subjects comprised 104 patients according to the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition （DSM-IV） criteria for major depressive disorder. The clinical efficacy and side effects were assessed on 1 week,2 weeks,4 weeks after citalopram treatment. PCR and DNA sequencing analysis were used to detect the genotype of PKB. SPSS13.0 statistic software was used to statistic analysis. Results ① An association was found between PKBα rs2494738 and citalopram antidepressant effect （alleles：OR = 0.139, P= 0.011 ） ;and the major depressive disorders patient carrying G alleles showed the better effect of citalopram treatment than individual carrying A allele. ②A weak association was revealed between the genotype of rs2494738 and adverse dry mouth（ Х^2 = 6. 730, P = 0. 035 ）. Conclusion The PKBα rs2494738 polymorphism may associate with citalopram antidepressant effica- cy and side effects.